Editorial: Pharma action needed as public admit R&D ignorance
This article was originally published in Scrip
The development of new medicines cannot take place without the involvement of the public, but getting people on board is more challenging if they don't understand the process or their role in it.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.